Clinical trials: Bleeding Diathesis
Hemophilia B, Hemophilia B, Moderately Severe or Severe
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately…
- Trial name
- NCT06611436
- Testing
- BE-101
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Be Biopharma
Myeloproliferative Neoplasms (MPNs)
WELL-MPN: A Digital Lifestyle App for Patients With MPNs
The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs).
- Trial name
- WELL-MPN (NCT07349134)
- Testing
- WELL-MPN Digital App
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Brigham and Women's Hospital
Coagulation Disorder, Carcinomatosis
Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)
Cytoreductive surgery (CRC) with intraperitoneal hyperthermal chemotherapy (HIPEC) has been shown to improve survival in selected patients with peritoneal carcinomatosis.
- Trial name
- HIPEC-COAG (NCT03956836)
- Testing
- ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Hospitales Universitarios Virgen del Rocío
Liver Cirrhosis, Portal Hypertension
Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement
Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients…
- Trial name
- PORTHEMOST (NCT07439939)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hemophilia A
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several…
- Trial name
- EmiMSK (NCT04131036)
- Testing
- assessment of joint health and bone density
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Washington Institute for Coagulation
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- ONE (NCT00703911)
- Testing
- eptacog alfa (activated)
- Where
- 16 sites in Algeria, Austria and 14 more
- Volunteers
- 102 people
- Sponsor
- Novo Nordisk A/S
Purpura, Thrombocytopaenic, Idiopathic
Drug Use Investigation for REVOLADE (ITP)
To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety…
- Trial name
- NCT01416311
- Testing
- Eltrombopag
- Volunteers
- 5,797 people
- Sponsor
- Novartis Pharmaceuticals
Hemophilia A
Study Evaluating Pharmacovigilance Of Refacto AF
The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.
- Trial name
- NCT00895037
- Testing
- ReFacto AF (Moroctocog alfa)
- Where
- 24 sites in Austria, Germany
- Volunteers
- 101 people
- Sponsor
- Pfizer
Polycythemia Vera, Essential Thrombocythemia
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to…
- Trial name
- NCT01970930
- Testing
- Blood specimen
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hemophilia A
A Study of BAX 888 in Male Adults With Severe Hemophilia A
The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A in male adults.
- Trial name
- NCT03370172
- Testing
- BAX 888
- Where
- 26 sites in United States, Austria and 4 more
- Volunteers
- 4 people
- Sponsor
- Baxalta now part of Shire
Protein C Deficiency
Ghrelin Levels in Patients With Protein C Deficiency
In rodents with protein C deficiency elevated levels of ghrelin has been observed. The purpose of this study is to investigate if patients with protein C deficiency also have elevated levels of ghrelin, and if so, how this…
- Trial name
- NCT04180657
- Testing
- Protein C deficiency
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Healthy
A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
The purpose of this study is to assess the use of 2 different Prothrombin Complex Concentrates (PCCs) on their ability to reverse (normalize) the pharmacodynamic effects of rivaroxaban in healthy adult volunteers.
- Trial name
- NCT01656330
- Testing
- Rivaroxaban 20 mg twice daily, Rivaroxaban 20 mg once daily, Profilnine SD
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Ehlers-Danlos Syndrome, EDS
Characterization of Bleeding Disorders in EDS
Ehlers-Danlos Syndrome (EDS) is a disease that weakens the connective tissues (i.e. tendons and ligaments) in the human body. EDS can make the joints loose and alter skin and wound healing.
- Conditions
- Ehlers-Danlos Syndrome, EDS, Classical Ehlers-Danlos Syndrome, Classical EDS (cEDS)
- Trial name
- NCT05434728
- Testing
- 20 ml venous blood collection
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
Purpura, Thrombotic Thrombocytopenic
Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Congenital thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman Syndrome or hereditary or familial TTP is a rare, but severe disease.
- Trial name
- NCT01754545
- Sponsor
- St. Olavs Hospital
Liposuction, Bruising
Bridging the Healing Gap: A Single-Blind Clinical Trial Assessing the Efficacy of Carboxy-gel in Reducing Bruising and Pain Post-Liposuction
The goal of this clinical trial is to evaluate if CO2 Lift reduces bruising and pain after Liposuction. The study also aims to explore changes in patient satisfaction.
- Conditions
- Liposuction, Bruising, Inflammation, Pain, Postoperative
- Trial name
- CO2L001 (NCT06791577)
- Testing
- Carboxytherapy
- Where
- 3 sites in Brazil, Colombia and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Total Definer Research Group
Hemophilia A, Prophylaxis of Bleeding
Prophylaxis Regimen for Hemophilia A Patients
Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lack of a protein in the blood called "clotting factor 8" (FVIII).
- Trial name
- PREDICT (NCT05036278)
- Testing
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- Bayer
Primary Immune Thrombocytopenia
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP…
- Trial name
- NCT06900920
- Testing
- TQB3473 Tablets
- Where
- 53 sites in China
- Volunteers
- 199 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP)
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
This is a single arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA(BZE2204) in…
- Conditions
- Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE)
- Trial name
- NCT07174843
- Testing
- CD19/CD22/BCMA CAR-T cells(BZE2204)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Trauma, Coagulation Defect; Bleeding
Quantra® System With the QStat® Cartridge in Trauma
This is a prospective, single-center, observational study to assess the Quantra QStat System in trauma patients.
- Trial name
- NCT05376462
- Testing
- Quantra System with the QStat Cartridge
- Where
- France
- Volunteers
- 36 people
- Sponsor
- HemoSonics LLC
Congenital Bleeding Disorder, Haemophilia A
Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
This trial is conducted in Europe and Japan. The aim of this trial is to assess the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of single doses of NNC128-0000-2011, when administered i.v.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Trial name
- NCT01288391
- Testing
- NNC 0128-0000-2011
- Where
- 3 sites in Germany, Japan and 1 more
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.